PMID: 7635997Jun 1, 1995Paper

Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men

Journal of Clinical Psychopharmacology
C L DerryR B Smith


This study was designed to determine whether differences in alpha-1 acid glycoprotein and free drug concentrations result in an altered response to triazolam. Twelve normal-weight and 12 obese adult male subjects received intravenous doses of triazolam, 0.5 mg, on two occasions separated by 1 week. There was a small difference in the alpha-1 acid glycoprotein concentrations between groups but no difference in free fraction of triazolam. There was a longer terminal half-life (t1/2 beta) in the obese subjects (3.16 +/- 0.87 vs. 3.83 +/- 1.24, p = 0.0098). Overall, week 1 data revealed no difference in effect between normal and obese subjects. However, response data reveal a pattern of increased sensitivity with the second exposure to triazolam. For example, area under the effect curve (AUEC) on all tests was significantly greater in week 2 for both groups of subjects. For a memory test and sedation from 0 to 12 hours, AUEC/free AUC ratios were significantly greater in week 2 for all subjects. The obese had a higher ratio on week 2 than on week 1 for all psychomotor tests and sedation (0 to 4.5 hours; p < 0.05). The results of modeling psychomotor impairment-concentration data pooled by group for each week continue the pattern: we...Continue Reading


Apr 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·K YamaokaT Uno
May 1, 1992·Clinical Pharmacology and Therapeutics·V D SchmithP D Kroboth
Jun 1, 1989·Clinical Pharmacokinetics·P D Garzone, P D Kroboth
May 1, 1989·Pharmacology, Biochemistry, and Behavior·S M AntelmanS Knopf
Jan 1, 1989·Pharmacology & Toxicology·J S Schou
Oct 1, 1989·Journal of Clinical Psychopharmacology·P D Kroboth, R B Smith
Jan 1, 1988·Fundamental & Clinical Pharmacology·G Cheymol
Nov 1, 1987·Journal of Clinical Pharmacology·G CheymolJ Dry
Dec 1, 1987·Journal of Clinical Pharmacology·R B SmithP D Varner
May 1, 1986·Clinical Pharmacokinetics·D R Abernethy, D J Greenblatt
Jul 1, 1985·Journal of Pharmaceutical Sciences·R L Yost, C L DeVane
Dec 1, 1985·Annals of Internal Medicine·T B Van Itallie
Jan 1, 1981·Clinical Pharmacology and Therapeutics·F S EbertsR W Vliek
Mar 1, 1983·The Journal of Pharmacy and Pharmacology·L J Moschitto, D J Greenblatt
Jul 1, 1983·Drug Intelligence & Clinical Pharmacy·P D Kroboth, R P Juhl
Jan 1, 1983·British Journal of Clinical Pharmacology·W H ZieglerM Eckert
Mar 1, 1984·Clinical Pharmacokinetics·D R AbernethyR I Shader
Sep 1, 1984·Clinical Pharmacology and Therapeutics·P D KrobothR P Juhl
Dec 1, 1984·British Journal of Clinical Pharmacology·I H BenedekP J McNamara
Dec 1, 1983·British Journal of Clinical Pharmacology·I H BenedekP J McNamara
Jan 1, 1982·Psychopharmacology·L C Johnson, D A Chernik
Oct 1, 1993·Annals of Internal Medicine·F X Pi-Sunyer


Apr 9, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·S M Antelman, S Gershon
Dec 14, 2002·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·J L C M DorneA G Renwick
Oct 6, 2000·Clinical Pharmacokinetics·G Cheymol
Jan 14, 2010·Clinical Pharmacokinetics·Michael J HanleyDavid J Greenblatt
Mar 23, 2011·Expert Opinion on Drug Metabolism & Toxicology·Glynn A MorrishBruce Green
Apr 27, 2011·Best Practice & Research. Clinical Anaesthesiology·Yigal LeykinTommaso Pellis
Sep 21, 2010·Contraception·Alison B EdelmanFrank Z Stanczyk
Oct 17, 2008·Cancer Treatment Reviews·Rodney J HunterJudith A Smith
Dec 2, 2011·British Journal of Clinical Pharmacology·Jennifer H MartinDavid Looke
Apr 6, 2005·Journal of Clinical Anesthesia·Andrea Casati, Marta Putzu
Sep 30, 2005·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·H C RawdenJ B Houston
Apr 27, 2017·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Miaoran Ning, Hyunyoung Jeong
Jun 3, 2011·Clinical Pharmacology and Therapeutics·R JainC G Sahajwalla
Jun 14, 2006·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·E M HowgateA Rostami-Hodjegan
Nov 21, 2017·Journal of Pain and Symptom Management·Neha M KramerKeith M Swetz

Related Concepts

Dose-Response Relationship, Drug
Psychological Tests (Procedure)
Psychomotor Performance

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Laryngeal Neoplasms

Laryngeal Neoplasms occur in the Larynx and are typically associated with smoking and alcohol consumption. Discover the latest research on Laryngeal Neoplasms here.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.